SCHEMBL2376874

SCHEMBL2376874

NC1=NC2(CC(c3ccccc3)Oc3ccc(Br)cc32)C(=O)N1Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 11/20 0.42
CTSD P07339 3/20 0.42
BACE2 Q9Y5Z0 1/20 0.41
KCNH2 Q12809 1/20 0.40
SCN9A Q15858 1/20 0.39
AKR1B1 P15121 1/20 0.38
PTPN1 P18031 2/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
CYP19A1 P11511 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376968 0.89 BACE1 (0.45) BACE1CTSDBACE2KCNH2AKR1B1
SCHEMBL7960752 0.89 BACE1 (0.41) BACE1CTSDBACE2SCN9AAKR1B1
SCHEMBL2375565 0.88 BACE1 (0.46) BACE1CTSDBACE2KCNH2AKR1B1
SCHEMBL2375775 0.88 BACE1 (0.46) BACE1CTSDBACE2KCNH2AKR1B1
SCHEMBL2376665 0.87 BACE1 (0.36) BACE1CTSDKCNH2SCN9AAKR1B1
SCHEMBL2375593 0.87 BACE1 (0.46) BACE1CTSDBACE2KCNH2AKR1B1
SCHEMBL2375642 0.86 BACE1 (0.42) BACE1CTSDBACE2KCNH2SCN9A
SCHEMBL2375532 0.85 SCN9A (0.43) BACE1CTSDBACE2SCN9AAKR1B1
SCHEMBL7948175 0.85 BACE1 (0.59) BACE1CTSDBACE2
SCHEMBL1829267 0.85 BACE1 (0.59) BACE1CTSDBACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2013-11-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP BACE1 1/4885CTSD 43/4885BACE2 2/4885
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APP BACE1 1/4885CTSD 43/4885BACE2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.